Copyright
©The Author(s) 2022.
World J Gastroenterol. Jun 14, 2022; 28(22): 2509-2522
Published online Jun 14, 2022. doi: 10.3748/wjg.v28.i22.2509
Published online Jun 14, 2022. doi: 10.3748/wjg.v28.i22.2509
Table 2 Descriptive statistics of the proportion of subjects with adverse events
| Placebo group (n = 226) | Probiotic group (n = 230) | |
| Causality with the study product not excluded | 13 (5.8) | 15 (6.5) |
| Causality with the research not excluded | 1 (0.4) | 2 (0.9) |
| Serious | 2 (0.9) | 1 (0.4) |
| Severe | 12 (5.3) | 17 (7.4) |
| Moderate | 55 (24.3) | 74 (32.2) |
| Mild | 39 (17.3) | 46 (20.0) |
- Citation: Mourey F, Decherf A, Jeanne JF, Clément-Ziza M, Grisoni ML, Machuron F, Legrain-Raspaud S, Bourreille A, Desreumaux P. Saccharomyces cerevisiae I-3856 in irritable bowel syndrome with predominant constipation. World J Gastroenterol 2022; 28(22): 2509-2522
- URL: https://www.wjgnet.com/1007-9327/full/v28/i22/2509.htm
- DOI: https://dx.doi.org/10.3748/wjg.v28.i22.2509